NZ565172A - Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS - Google Patents

Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS

Info

Publication number
NZ565172A
NZ565172A NZ565172A NZ56517206A NZ565172A NZ 565172 A NZ565172 A NZ 565172A NZ 565172 A NZ565172 A NZ 565172A NZ 56517206 A NZ56517206 A NZ 56517206A NZ 565172 A NZ565172 A NZ 565172A
Authority
NZ
New Zealand
Prior art keywords
targeted
targeted tumor
tumor stem
cell
tumor
Prior art date
Application number
NZ565172A
Other languages
English (en)
Inventor
Angelo Luigi Vescovi
Brent Allan Reynolds
Original Assignee
Stemgen S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemgen S P A filed Critical Stemgen S P A
Priority to NZ598031A priority Critical patent/NZ598031A/xx
Publication of NZ565172A publication Critical patent/NZ565172A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ565172A 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS NZ565172A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ598031A NZ598031A (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70085905P 2005-07-19 2005-07-19
PCT/IB2006/002296 WO2007010394A2 (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps

Publications (1)

Publication Number Publication Date
NZ565172A true NZ565172A (en) 2012-12-21

Family

ID=37420973

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ565172A NZ565172A (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS
NZ598031A NZ598031A (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ598031A NZ598031A (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps

Country Status (13)

Country Link
US (2) US9220756B2 (enExample)
EP (2) EP3117833B1 (enExample)
JP (3) JP5189977B2 (enExample)
KR (2) KR101311061B1 (enExample)
AU (1) AU2006271308B2 (enExample)
CA (2) CA2790675C (enExample)
DK (2) DK3117833T3 (enExample)
ES (2) ES2686093T3 (enExample)
HR (1) HRP20181379T1 (enExample)
HU (2) HUE040063T2 (enExample)
NZ (2) NZ565172A (enExample)
PL (2) PL3117833T3 (enExample)
WO (1) WO2007010394A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2790675C (en) * 2005-07-19 2016-12-20 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
EP2259792B1 (en) * 2008-02-13 2011-10-05 DKFZ Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Bone morphogenetic proteins for use in treating and preventing neuroblastomas
WO2017032856A2 (en) 2015-08-25 2017-03-02 Histide Ag Compounds for inducing tissue formation and uses thereof
JP6890835B2 (ja) * 2015-09-17 2021-06-18 ヒスタイド アクツィエンゲゼルシャフト 腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用
CN109715192B (zh) * 2015-09-17 2024-02-20 伊斯迪德股份公司 用于将赘生性细胞转化为非赘生性细胞的药物结合物及其用途
KR20180050744A (ko) * 2015-09-17 2018-05-23 히스티드 아게 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도
WO2017046226A2 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof.
HUE057153T2 (hu) * 2015-09-17 2022-04-28 Histide Ag Neoplasztikus sejt nem neoplasztikus sejtté alakításához használt gyógyszerészeti együttes, mely egy növekedésifaktor-receptor agonistából és egy adhéziós fehérjeinhibitorból áll, és ezek felhasználása
JP7457331B2 (ja) * 2018-12-28 2024-03-28 国立大学法人 東京大学 神経膠腫の治療および予防剤、脳腫瘍の悪性度のマーカーおよび脳腫瘍の予後マーカー、脳腫瘍の悪性度および予後の判定方法並びに腫瘍増殖を抑制する抗体

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
EP0620736B1 (en) * 1991-12-24 2001-03-07 Amrad Corporation Limited Use of leukemia inhibiting factor (lif) for the treatment of tumours and sarcomas
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US7592428B1 (en) * 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
EP0756628B1 (en) * 1994-04-29 2007-11-14 Curis, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6281015B1 (en) * 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6036920A (en) 1996-05-09 2000-03-14 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay apparatus for ligand development and multi-variable protein chemistry optimization
EP1131087B2 (en) * 1998-11-13 2009-04-01 Stryker Corporation Alleviatation of prostate cancer symptoms
CA2393252A1 (en) * 1999-12-06 2001-06-07 Paul Calabresi Use of methylol-containing compounds to treat tumors
CA2401989A1 (en) * 2000-03-03 2001-09-07 The Walter And Eliza Hall Institute Of Medical Research A method of treatment
CN1867678B (zh) 2003-09-12 2012-10-03 干细胞技术公司 神经集落形成分析
JP2005098727A (ja) 2003-09-22 2005-04-14 Hosiden Corp 振動センサ
EP1697715A4 (en) 2003-12-05 2007-10-10 Univ Leland Stanford Junior IDENTIFICATION, ISOLATION AND ELIMINATION OF CANCER STEM CELLS
EP1773871B1 (en) * 2004-06-17 2014-10-15 Thrasos Innovation, Inc. Tdf-related compounds and analogs thereof
CA2790675C (en) * 2005-07-19 2016-12-20 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
US10130590B2 (en) * 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds

Also Published As

Publication number Publication date
JP5189977B2 (ja) 2013-04-24
AU2006271308B2 (en) 2012-12-20
KR101311061B1 (ko) 2013-09-25
HUE042197T2 (hu) 2019-06-28
CA2790675C (en) 2016-12-20
PL1904093T3 (pl) 2018-12-31
ES2686093T3 (es) 2018-10-16
EP1904093A2 (en) 2008-04-02
KR101338533B1 (ko) 2013-12-12
PL3117833T3 (pl) 2019-06-28
HRP20181379T1 (hr) 2018-11-16
JP2009502771A (ja) 2009-01-29
KR20120125990A (ko) 2012-11-19
US9220756B2 (en) 2015-12-29
US9737589B2 (en) 2017-08-22
CA2615491C (en) 2016-11-29
JP5891068B2 (ja) 2016-03-22
US20100167999A1 (en) 2010-07-01
ES2710601T3 (es) 2019-04-26
JP2015057452A (ja) 2015-03-26
HUE040063T2 (hu) 2019-02-28
CA2790675A1 (en) 2007-01-25
NZ598031A (en) 2013-11-29
EP3117833B1 (en) 2019-01-23
CA2615491A1 (en) 2007-01-25
WO2007010394A3 (en) 2007-08-30
US20160228511A1 (en) 2016-08-11
DK1904093T3 (en) 2018-09-03
EP3117833A1 (en) 2017-01-18
DK3117833T3 (en) 2019-03-18
EP1904093B1 (en) 2018-06-13
KR20080082595A (ko) 2008-09-11
JP2012107063A (ja) 2012-06-07
AU2006271308A1 (en) 2007-01-25
WO2007010394A2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
Deng et al. Bioceramic scaffolds with antioxidative functions for ROS scavenging and osteochondral regeneration
MY143795A (en) Tetrahydropyridoindole derivatives
WO2010053550A3 (en) Cxcr4 receptor compounds
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
TR201903587T4 (tr) Telomeraz aktivitesinin artırılması için bileşimler.
WO2005118544A3 (en) Cycloalkyl substituted pyrimidinediamine compounds and their uses
EA200802129A1 (ru) 6-о-замещенные бензоксазолы и бензотиазолы и способы подавления передачи сигналов от csf-1r
DE60028970D1 (de) An her2 bindende peptidverbindungen
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
WO2004013093A3 (en) Cytotoxic agents containing novel potent taxanes and their therapeutic use
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
MX2012003408A (es) Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2.
WO2007117161A1 (en) Substituted ring fused azines and their use in cancer therapy
JP2012107063A5 (enExample)
TN2009000194A1 (en) Novel antiproliferation antibodies
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
NZ565172A (en) Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS
MY144632A (en) Cytotoxic agents comprising new taxanes
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
EA200702253A1 (ru) Фармацевтическая композиция
ATE514718T1 (de) Peptabody für krebsbehandlung
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 JUL 2013 BY CPA GLOBAL

Effective date: 20130511

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 JUL 2016 BY CPA GLOBAL

Effective date: 20130511

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JUL 2017 BY CPA GLOBAL

Effective date: 20160603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JUL 2018 BY CPA GLOBAL

Effective date: 20170608

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JUL 2019 BY CPA GLOBAL

Effective date: 20180717

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JUL 2020 BY DENNEMEYER + CO.

Effective date: 20191113

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JUL 2021 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20200727

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JUL 2022 BY DENNEMEYER + CO

Effective date: 20210715

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JUL 2023 BY DENNEMEYER + CO

Effective date: 20220716

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JUL 2024 BY DENNEMEYER + CO. SARL

Effective date: 20230710

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JUL 2025 BY DENNEMEYER AND CO. SARL

Effective date: 20240708

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JUL 2026 BY DENNEMEYER + CO. SARL

Effective date: 20250718